Stephen Hoge - Jun 14, 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Jun 14, 2021
Transactions value $
-$4,147,500
Form type
4
Date filed
6/15/2021, 04:33 PM
Previous filing
Jun 4, 2021
Next filing
Jun 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $54.5K +5K +0.31% $10.90* 1.61M Jun 14, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $54.5K +5K +0.31% $10.90* 1.62M Jun 14, 2021 Direct F1
transaction MRNA Common Stock Options Exercise $9.9K +10K +0.62% $0.99* 1.63M Jun 14, 2021 Direct F1
transaction MRNA Common Stock Sale -$4.27M -20K -1.23% $213.32 1.61M Jun 14, 2021 Direct F1
holding MRNA Common Stock 4.12K Jun 14, 2021 By Valhalla, LLC
holding MRNA Common Stock 152K Jun 14, 2021 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.63% $0.00 302K Jun 14, 2021 Common Stock 5K $10.90 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -1.66% $0.00 297K Jun 14, 2021 Common Stock 5K $10.90 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -2.19% $0.00 447K Jun 14, 2021 Common Stock 10K $0.99 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
F2 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F3 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter.
F4 This option is fully vested and exercisable.